序贯外用糠酸莫米松乳膏与克立硼罗软膏治疗轻中度老年特应性皮炎的疗效和安全性

doi:10.3969/j.issn.1003-9198.2025.10.017

Abstract

Abstract: Objective To evaluate the therapeutic effect, safety and recurrence rate of mild to moderate atopic dermatitis (AD) in the elderly treated with sequential topical application of 0.1% mometasone furoate cream and 2% crisaborole ointment. Methods The clinical data of 209 elderly outpatients with mild to moderate AD who were diagnosed and treated at the Department of Dermatology of Geriatric Hospital of Nanjing Medical University from July 2022 to August 2024 were retrospectively analyzed. According to different medication regimens, they were divided into three groups: sequential treatment group (n=73), mometasone furoate group (n=68), and crisaborole group (n=68). The scores of Scoring Atopic Dermatitis (SCORAD) before and after treatment, pruritus visual analogue scale (VAS), the clinical efficacy, pruritus relief indices, adverse reactions after treatment and recurrence rate 4 weeks after discontinuation were observed and compared among the three groups. Results After 4 weeks of treatment, the SCORAD score and efficacy index showed no significant differences between the three groups, however, showing significant differences between both groups and the crisaborole group(P＜0.001). The effective rate showed no significant differences between the sequential treatment group and the mometasone furoate group and the crisaborole group.The adverse reaction rate was lower in the sequential treatment group than that in the mometasone furoate group(8.2% vs 25.0%, P＜0.05). Four weeks after discontinuation, the recurrence rate showed significant difference among the three groups(P＜0.05), and the mometasone furoate group presented with the highest rate, followed by the sequential treatment group and the crisaborole group. Conclusions The sequential topical application of 0.1% mometasone furoate cream and 2% crisaborole ointment in treating mild to moderate AD in the elderly shows significant clinical efficacy, a low recurrence rate, and minimal adverse reactions, which is a promising option for clinical practice.

Key words: atopic dermatitis, aged, crisaborole ointment, mometasone furoate cream

CLC Number:

R 758.23

XIU Yanyan, HAN Shanshan, LIU Xin. Efficacy and safety of sequential topical application of mometasone furoate cream and crisaborole ointment in the treatment of mild to moderate atopic dermatitis in the elderly[J]. Practical Geriatrics, 2025, 39(10): 1052-1056.

References

[1] SAEKI H, OHYA Y, FURUTA J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021[J]. Allergol Int, 2022, 71(4): 448-458.
[2] LAUGHTERM R, MAYMONE M C, MASHAYEKHI S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990-2017[J]. Br J Dermatol, 2021, 184(2): 304-309.
[3] WILLIAMSON S, MERRITT J, DE BENEDETTO A. Atopic dermatitis in the elderly: a review of clinical and pathophysiological hallmarks[J]. Br J Dermatol, 2020, 182(1): 47-54.
[4] WANG S, ZHU R, GU C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China[J]. J Eur Acad Dermatol Venereol, 2020, 34(10): 2346-2352.
[5] YOUSAF M, AYASSE M, AHMED A, et al. Association between atopic dermatitis and hypertension: a systematic review and meta-analysis[J]. Br J Dermatol, 2022, 186(2): 227-235.
[6] SILVERBERGJ I, GELFANDJ M, MARGOLISD J, et al. Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults[J]. Ann Allergy Asthma Immunol, 2018, 121(5): 604-612.e3.
[7] PALLER A, JAWORSKIJ C, SIMPSONE L, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders[J]. Am J Clin Dermatol, 2018, 19(6): 821-838.
[8] HE H, LI R, CHOI S, et al. Increased cardiovascular and atherosclerosis markers in blood of older patients with atopic dermatitis[J]. Ann Allergy Asthma Immunol, 2020, 124(1): 70-78.
[9] UMAR B U, RAHMAN S, DUTTA S, et al. Management of atopic dermatitis: the role of tacrolimus[J]. Cureus, 2022, 14(8): e28130.
[10] CHU D K, CHU A W L, RAYNER D G, et al.Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials[J]. J Allergy Clin Immunol, 2023, 152(6):1493-1519.
[11] 中华医学会皮肤性病学分会免疫学组,特应性皮炎协作研究中心. 中国特应性皮炎诊疗指南(2020版)[J]. 中华皮肤科杂志,2020,53(2): 81-88.
[12] 姚煦. 常用特应性皮炎严重度评估方法[J]. 中华皮肤科杂志, 2021,54(6): 539-541.
[13] BIEBER T, D’ERMEA M, AKDISC A, et al. Clinical phenotypes and endophenotypes of atopic dermatitis: where are we, and where should wego?[J]. J Allergy Clin Immunol, 2017, 139(4S): S58-S64.
[14] 中华医学会皮肤病学分会免疫学组. 老年特应性皮炎诊疗专家共识(2023版)[J]. 中华皮肤科杂志,2023,56(11):991-999.
[15] LANGANS M, IRVINEA D, WEIDINGER S. Atopic dermatitis[J]. Lancet, 2020, 396(10247): 345-360.
[16] TANEI R, KATSUOKA K. Clinical analyses of atopic dermatitis in the aged[J]. J Dermatol, 2008, 35(9): 562-569.
[17] AAAAI/ACAAI JTF Atopic Dermatitis Guideline Panel, CHUD K, SCHNEIDER L, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on practice parameters GRADE- and institute of medicine-based recommendations[J]. Ann Allergy Asthma Immunol, 2024, 132(3): 274-312.
[18] RIAHI A, LAM J M. Crisaborole 2% ointment for mild-to-moderate atopic dermatitis[J]. Skin Therapy Lett, 2021, 26(1): 1-4.
[19] JARNAGIN K, CHANDA S, CORONADO D, et al. Crisaborole topical ointment, 2%: a nonsteroidal, topical, anti-inflammatory phosphodiesterase 4 inhibitor in clinical development for the treatment of atopic dermatitis[J]. J Drugs Dermatol, 2016, 15(4): 390-396.
[20] WOLLENBERG A, KINBERGER M, ARENTS B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations[J]. J Eur Acad Dermatol Venereol, 2022, 36(11): 1904-1926.
[21] 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组,中华医学会皮肤性病学分会儿童学组,中国老年保健医学研究会皮肤科分会. 特应性皮炎外用制剂合理应用及患者指导专家共识[J].中华皮肤科杂志,2022,55(4):281-288.

Efficacy and safety of sequential topical application of mometasone furoate cream and crisaborole ointment in the treatment of mild to moderate atopic dermatitis in the elderly

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Recommended 10

[1]	WANG Meijuan, JIANG Xuezhong, WANG Yi. Advances in the treatment of deep vein thrombosis in the elderly [J]. Practical Geriatrics, 2025, 39(9): 865-870.
[2]	ZHANG Yidan, YANG Jian, LIU Jiao, LI Xia, GONG Li, YAO Jing. Advances in imaging diagnosis of deep vein thrombosis in the elderly [J]. Practical Geriatrics, 2025, 39(9): 871-875.
[3]	DU Haiwen, ZHANG Yidan, LI Xia, LIU Jiao, WEI Shuping. Advances in the epidemiology and risk factors of deep venous thrombosis in the elderly [J]. Practical Geriatrics, 2025, 39(9): 879-882.
[4]	QIAN Jing, YAN Xiaodi, SHEN Chaoyan, YAO Ninghua, SHI Yu, BIAN Yinzhu. Study on the expression of ANLN in tissues of elderly patients with pancreatic cancer and its mechanism of action on pancreatic cancer cells [J]. Practical Geriatrics, 2025, 39(9): 888-893.
[5]	ZHANG Yuwen, CHEN Lijian. Effects of crystalloid preloading and colloid preloading on hemodynamics and early postoperative cognitive function in elderly patients undergoing painless colonoscopy [J]. Practical Geriatrics, 2025, 39(9): 894-898.
[6]	HUANG Yong, WANG Fengfeng, SHI Bosheng, HUANG Li, WANG Zhifei. Transcutaneous acupoint electrical stimulation for postoperative pain management and gastrointestinal function recovery in elderly patients with hip fractures [J]. Practical Geriatrics, 2025, 39(9): 910-914.
[7]	LYU Wenjun, KANG Jing, MO Fei. Study on the current status and influencing factors of activity of daily living in Chinese elderly people from the perspective of health ecology [J]. Practical Geriatrics, 2025, 39(9): 915-919.
[8]	YAN Zhenlong, HUANG Ping, CHEN Meng, TAO Junjie, WANG Yuchuan, CHEN Lili, FAN Ya, LI Zehua, ZHOU Xiaotian. Revision and reliability and validity verification of the Chinese version of Identification of Seniors At Risk in the department of emergency [J]. Practical Geriatrics, 2025, 39(9): 920-923.
[9]	ZHANG Ning, GAO Xiu, KANG Lin, LIU Xiaohong. Analysis of clinical characteristics of 17 elderly patients with pulmonary actinomycosis [J]. Practical Geriatrics, 2025, 39(9): 924-928.
[10]	MO Jun, ZHANG Siping, ZHANG Huanwen, LI Jianjiang, Dannier Abulimiti, HUANG Yifei. Efficacy of selective vertebroplasty in the treatment of multi-segment vertebral osteoporotic fractures [J]. Practical Geriatrics, 2025, 39(9): 929-932.
[11]	YAO Heling, WANG Yu, LI Wansong, LUO Hongjie, LYU Xiaolei,WANG Xin, FENG Lina. Clinical value of white matter hyperintensities for overactive bladder symptom in elderly patients with cerebral small vessel disease [J]. Practical Geriatrics, 2025, 39(9): 933-936.
[12]	YAO Yuan, YANG Yong. Advances in the mechanisms of immunosenescence in elderly patients with non-small cell lung cancer [J]. Practical Geriatrics, 2025, 39(9): 947-951.
[13]	ZHOU Dan, WEI Kexin, DENG Shu, HE Rui. Research progress on the prevention and treatment of venous thromboembolism in elderly using artificial intelligence and wearable devices [J]. Practical Geriatrics, 2025, 39(9): 963-967.
[14]	HE Xinxin, XIE Dongmei, WANG Xiaoling, LI Ying, GAO Langli. Research progress in the application of artificial intelligence in the care for disabled elderly [J]. Practical Geriatrics, 2025, 39(8): 757-761.
[15]	JIANG Huizeng, LIU Jinna, ZHANG Dandan, ZHANG Jie. Advances of the application of artificial intelligence in fall risk management in the elderly [J]. Practical Geriatrics, 2025, 39(8): 762-767.